Novo Nordisk Cash on Hand 2010-2023 | NVO

Novo Nordisk cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Novo Nordisk cash on hand for the quarter ending December 31, 2023 was $4.730B, a 27% increase year-over-year.
  • Novo Nordisk cash on hand for 2023 was $4.73B, a 27% increase from 2022.
  • Novo Nordisk cash on hand for 2022 was $3.724B, a 22.08% increase from 2021.
  • Novo Nordisk cash on hand for 2021 was $3.051B, a 56.1% increase from 2020.
Novo Nordisk Annual Cash on Hand
(Millions of US $)
2023 $4,730
2022 $3,724
2021 $3,051
2020 $1,954
2019 $2,348
2018 $2,422
2017 $3,214
2016 $3,154
2015 $3,090
2014 $2,841
2013 $2,848
2012 $2,944
2011 $3,271
2010 $2,862
2009 $2,402
Novo Nordisk Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $4,730
2023-09-30 $7,402
2023-06-30 $5,699
2023-03-31 $4,382
2022-12-31 $3,724
2022-09-30 $5,784
2022-06-30 $4,953
2022-03-31 $3,330
2021-12-31 $3,051
2021-09-30 $5,846
2021-06-30 $4,555
2021-03-31 $1,430
2020-12-31 $1,954
2020-09-30 $4,265
2020-06-30 $3,785
2020-03-31 $1,442
2019-12-31 $2,348
2019-09-30 $2,886
2019-06-30 $2,197
2019-03-31 $1,421
2018-12-31 $2,422
2018-09-30 $2,597
2018-06-30 $3,048
2018-03-31 $2,103
2017-12-31 $3,214
2017-09-30 $3,430
2017-06-30 $3,415
2017-03-31 $2,591
2016-12-31 $3,154
2016-09-30 $2,571
2016-06-30 $2,402
2016-03-31 $1,518
2015-12-31 $3,090
2015-09-30 $2,698
2015-06-30 $1,811
2015-03-31 $1,128
2014-12-31 $2,841
2014-09-30 $2,426
2014-06-30 $1,239
2014-03-31 $1,122
2013-12-31 $2,848
2013-09-30 $2,604
2013-06-30 $2,100
2013-03-31 $2,086
2012-12-31 $2,944
2012-09-30 $2,967
2012-06-30 $2,146
2012-03-31 $2,361
2011-12-31 $3,271
2011-09-30 $3,402
2011-06-30 $3,183
2011-03-31 $2,678
2010-12-31 $2,862
2010-09-30 $2,247
2010-06-30 $2,049
2010-03-31 $1,893
2009-12-31 $2,402
2009-09-30 $2,278
2009-06-30 $1,821
2009-03-31 $1,630
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $558.743B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.503B 83.83
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53